STNT News Alert Stevia Nutra Corp (STNT) 0.0017 02/15/2015 1
Post# of 64074
Posted On: 02/15/2015 3:32:53 PM
Stevia Nutra Corp (STNT) 0.0017 $STNT
STENTYS Expands Benefits of First Drug-Eluting, Self-Expanding Stent to Lower Limb Artery Disease
Business Wire - Wed Jan 28, 11:25AM CST
STENTYS (Paris:STNT) (FR0010949404 -- STNT), a medical technology company commercializing the world's first and only Self-Apposing(R) coronary stent, today announced that its unique Drug-Eluting and Self-Expanding stent was evaluated in 70 patients suffering from critical limb ischemia (CLI) and prevented foot amputation in 99% of them.
STENTYS Expands Product Offering To All Coronary Stent Indications Through Exclusive Agreement With Micell To Distribute Its Novel Drug-Eluting Stent
Business Wire - Mon Nov 03, 10:54AM CST
Regulatory News :
STENTYS' Sirolimus-Eluting Stent Receives CE Marking
Business Wire - Mon Oct 27, 12:50PM CDT
Regulatory News:
STENTYS Revenues for the First 9 Months of 2014 up 16.9%
Business Wire - Thu Oct 23, 10:45AM CDT
STENTYS (Paris:STNT) (FR0010949404 -- STNT), a medical technology company commercializing, in Europe, the world's first and only Self-Apposing(R) stent to treat acute myocardial infarction (AMI), today announces revenues for the third-quarter and nine-months ended September 30, 2014.
STENTYS Wins Large Regional Tender in Middle East
Business Wire - Mon Oct 20, 12:17PM CDT
Regulatory News:
STENTYS Stent Continues to Show Low Mortality Two Years after Treatment of a Heart Attack
Business Wire - Tue Sep 16, 11:12AM CDT
Regulatory News :
STENTYS Reaches 10,000 Self-Apposing Stent implantations
Business Wire - Wed Sep 03, 11:06AM CDT
Regulatory News:
STENTYS First Half 2014 Revenues Rise 18%
Business Wire - Thu Jul 24, 10:45AM CDT
Regulatory News:
STENTYS Expands Benefits of First Drug-Eluting, Self-Expanding Stent to Lower Limb Artery Disease
Business Wire - Wed Jan 28, 11:25AM CST
STENTYS (Paris:STNT) (FR0010949404 -- STNT), a medical technology company commercializing the world's first and only Self-Apposing(R) coronary stent, today announced that its unique Drug-Eluting and Self-Expanding stent was evaluated in 70 patients suffering from critical limb ischemia (CLI) and prevented foot amputation in 99% of them.
STENTYS Expands Product Offering To All Coronary Stent Indications Through Exclusive Agreement With Micell To Distribute Its Novel Drug-Eluting Stent
Business Wire - Mon Nov 03, 10:54AM CST
Regulatory News :
STENTYS' Sirolimus-Eluting Stent Receives CE Marking
Business Wire - Mon Oct 27, 12:50PM CDT
Regulatory News:
STENTYS Revenues for the First 9 Months of 2014 up 16.9%
Business Wire - Thu Oct 23, 10:45AM CDT
STENTYS (Paris:STNT) (FR0010949404 -- STNT), a medical technology company commercializing, in Europe, the world's first and only Self-Apposing(R) stent to treat acute myocardial infarction (AMI), today announces revenues for the third-quarter and nine-months ended September 30, 2014.
STENTYS Wins Large Regional Tender in Middle East
Business Wire - Mon Oct 20, 12:17PM CDT
Regulatory News:
STENTYS Stent Continues to Show Low Mortality Two Years after Treatment of a Heart Attack
Business Wire - Tue Sep 16, 11:12AM CDT
Regulatory News :
STENTYS Reaches 10,000 Self-Apposing Stent implantations
Business Wire - Wed Sep 03, 11:06AM CDT
Regulatory News:
STENTYS First Half 2014 Revenues Rise 18%
Business Wire - Thu Jul 24, 10:45AM CDT
Regulatory News:
(0)
(0)Scroll down for more posts ▼